NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

MDxHealth SA (MDXH) Stock Analysis

MDxHealth SA (MDXH) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

MDXH

$0.75

+$0.02 (+3.03%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MDXH with… →

MDXH Key Statistics

As of Sep 4, 2026
Trading
Open
$0.72
Previous Close
$0.73
Day's Range
0.71–0.75
52-Week Range
0.40–5.33
Volume
270.10K
Valuation
Market Cap
$71.41M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.63
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.73
Financials (FY)
Revenue (FY)
$107.88M+19.80%
Net Income (FY)
−$33.52M
Profit marginThe share of revenue left as profit after all costs and taxes.
−32.74%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
95.42M
1-Year Return
−78.81%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
6.06M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MDXH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−79.05%
2025+50.63%
2024−39.85%
2023−40.39%
2022−30.57%
2021 (partial year)−20.67%

As of September 4, 2026.

MDXH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$107.88M−$33.52M−31.1%
2024$90.05M−$38.07M−42.3%
2023$70.19M−$43.10M−61.4%
2022$37.05M−$44.04M−118.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$107.88M$69.63M−$15.37M−$33.52M−31.1%
2024$90.05M$55.14M−$24.03M−$38.07M−42.3%
2023$70.19M$43.93M−$26.74M−$43.10M−61.4%
2022$37.05M$19.22M−$38.42M−$44.04M−118.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MDXH Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricMDXHDiagnostics & Research medianvs median
P/S ratio0.634.990.1x the median
Profit margin−32.74%0.00%32.7 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values MDxHealth SA (MDXH) at $71.41M. The company sits in the Healthcare sector, in the Diagnostics & Research industry. The company reports 364 employees.

The 52-week range on file runs from $0.40 to $5.33. The most recent close on file for MDXH is $0.75, dated September 4, 2026. That is +$0.02 (+3.03%) against the previous close. The latest close sits 87% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $107.88M. Against the prior fiscal year total of $90.05M, that is a change of +19.80%. The same year closed with a net loss of $33.52M. Profit margin runs at −32.74%. That is 32.7 percentage points below the Diagnostics & Research median of 0%. Trailing earnings per share are −0.73.

Across the 4 fiscal years on file, revenue moves from $37.05M in 2022 to $107.88M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 0.63 times revenue. On price-to-sales that is 0.1 times the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −78.81%. Across 3 years the annualized return works out at −38.65%. Annualized volatility over the trailing 4 years is 428.52%.

Growth & Income

No dividend is on file for MDXH.

Across the complete calendar years on file, 2025 returned +50.63% and 2023 returned −40.39%. Of the 4 complete calendar years on file, 1 finished higher. So far in 2026 the price is −79.05%.

Peer Comparison

MDxHealth SA (MDXH) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MDxHealth SA MDXH $71.41M —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. MDxHealth SA has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About MDxHealth SA

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Visit website →